Plasma AR and abiraterone-resistant prostate cancer

See allHide authors and affiliations

Science Translational Medicine  04 Nov 2015:
Vol. 7, Issue 312, pp. 312re10
DOI: 10.1126/scitranslmed.aac9511

Detecting resistance before it starts

Androgen receptor targeting is the cornerstone of prostate cancer treatment. Even when the tumors become “castration-resistant” or no longer sensitive to androgen deprivation, androgen signaling can still be effectively targeted by newer drugs such as abiraterone and enzalutamide, which also inhibit the androgen signaling axis. Romanel et al. analyzed tumor DNA samples from the blood of 97 patients with castration-resistant prostate cancer at different times during the course of treatment with abiraterone. Although some new mutations emerged during therapy, the authors found that androgen receptor amplifications were present from the beginning and correlated with abiraterone resistance, suggesting that detection of these amplifications should be useful for identifying abiraterone-resistant cancers before starting treatment.

View Full Text

Stay Connected to Science Translational Medicine